A detailed history of Charles Schwab Investment Management Inc transactions in Incyte Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,609,220 shares of INCY stock, worth $131 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,609,220
Previous 1,245,051 29.25%
Holding current value
$131 Million
Previous $75.5 Million 40.93%
% of portfolio
0.02%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$57.33 - $68.61 $20.9 Million - $25 Million
364,169 Added 29.25%
1,609,220 $106 Million
Q2 2024

Aug 12, 2024

SELL
$51.18 - $63.75 $4.09 Million - $5.09 Million
-79,908 Reduced 6.03%
1,245,051 $75.5 Million
Q1 2024

May 08, 2024

SELL
$56.55 - $66.59 $104,900 - $123,524
-1,855 Reduced 0.14%
1,324,959 $75.5 Million
Q4 2023

Feb 06, 2024

BUY
$52.16 - $64.19 $5.09 Million - $6.27 Million
97,614 Added 7.94%
1,326,814 $83.3 Million
Q3 2023

Nov 08, 2023

BUY
$57.77 - $65.93 $2.04 Million - $2.32 Million
35,240 Added 2.95%
1,229,200 $71 Million
Q2 2023

Aug 09, 2023

BUY
$60.95 - $75.51 $2.27 Million - $2.81 Million
37,252 Added 3.22%
1,193,960 $74.3 Million
Q1 2023

May 11, 2023

BUY
$70.23 - $86.01 $3.63 Million - $4.45 Million
51,693 Added 4.68%
1,156,708 $83.6 Million
Q4 2022

Feb 13, 2023

BUY
$67.18 - $84.11 $1.73 Million - $2.16 Million
25,678 Added 2.38%
1,105,015 $88.8 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $236,990 - $296,721
3,581 Added 0.33%
1,079,337 $71.9 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $1.88 Million - $2.37 Million
-28,449 Reduced 2.58%
1,075,756 $81.7 Million
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $3.09 Million - $3.73 Million
46,823 Added 4.43%
1,104,205 $87.7 Million
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $4.1 Million - $4.8 Million
64,720 Added 6.52%
1,057,382 $77.6 Million
Q3 2021

Nov 16, 2021

BUY
$68.67 - $84.02 $4.49 Million - $5.49 Million
65,393 Added 7.05%
992,662 $68.3 Million
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $2.74 Million - $3 Million
34,274 Added 3.84%
927,269 $78 Million
Q1 2021

May 17, 2021

SELL
$76.02 - $100.5 $2.53 Million - $3.35 Million
-33,332 Reduced 3.6%
892,995 $72.6 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $303,501 - $367,254
3,759 Added 0.41%
926,327 $80.6 Million
Q3 2020

Nov 13, 2020

BUY
$85.07 - $109.69 $1.46 Million - $1.88 Million
17,142 Added 1.89%
922,568 $82.8 Million
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $2.86 Million - $4.2 Million
-38,600 Reduced 4.09%
905,426 $94.1 Million
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $1.87 Million - $2.55 Million
-29,634 Reduced 3.04%
944,026 $69.1 Million
Q4 2019

Feb 07, 2020

BUY
$73.04 - $95.72 $2.1 Million - $2.76 Million
28,795 Added 3.05%
973,660 $85 Million
Q3 2019

Nov 08, 2019

BUY
$72.82 - $86.52 $6.55 Million - $7.78 Million
89,927 Added 10.52%
944,865 $70.1 Million
Q2 2019

Aug 09, 2019

BUY
$73.52 - $88.7 $2.33 Million - $2.81 Million
31,680 Added 3.85%
854,938 $72.6 Million
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $10.1 Million - $14 Million
158,453 Added 23.83%
823,258 $70.8 Million
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $1.2 Million - $1.43 Million
20,446 Added 3.17%
664,805 $42.3 Million
Q3 2018

Nov 13, 2018

BUY
$61.75 - $74.23 $664,306 - $798,566
10,758 Added 1.7%
644,359 $44.5 Million
Q2 2018

Aug 08, 2018

BUY
$60.85 - $83.98 $2.3 Million - $3.18 Million
37,841 Added 6.35%
633,601 $42.5 Million
Q1 2018

May 07, 2018

BUY
$83.06 - $100.98 $1.29 Million - $1.56 Million
15,493 Added 2.67%
595,760 $49.6 Million
Q4 2017

Jan 17, 2018

BUY
$93.56 - $116.6 $3.35 Million - $4.18 Million
35,815 Added 6.58%
580,267 $55 Million
Q3 2017

Nov 13, 2017

BUY
$109.15 - $138.27 $59.4 Million - $75.3 Million
544,452
544,452 $63.6 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $18.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.